We are live on ! Find out more
TRCT

Tower Research Capital (TRC) Portfolio holdings

AUM $4.08B
1-Year Est. Return 58.77%
This Fund
S&P 500
This Quarter Est. Return
+9.34%
1 Year Est. Return
+58.77%
3 Year Est. Return
+143.94%
5 Year Est. Return
+167.17%
10 Year Est. Return
+536.06%
AUM
$9.03B
AUM Growth
+$6.6B
Cap. Flow
+$1.53B
Cap. Flow %
16.94%
Top 10 Hldgs %
64.29%
Holding
5,395
New
546
Increased
3,017
Reduced
1,240
Closed
466

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$487M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$48.2M
3
EEM icon
iShares MSCI Emerging Markets ETF
EEM
+$29.4M
4
EFA icon
iShares MSCI EAFE ETF
EFA
+$28.9M
5
MSFT icon
Microsoft
MSFT
+$27.7M

Top Sells

Rank Stock Value
1
VXX icon
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
+$51.8M
2
VOO icon
Vanguard S&P 500 ETF
VOO
+$38.5M
3
SOXL icon
Direxion Daily Semiconductor Bull 3X ETF
SOXL
+$32.6M
4
IVV icon
iShares Core S&P 500 ETF
IVV
+$21M
5
VTI icon
Vanguard Morningstar Total Stock Market ETF
VTI
+$16.6M

Sector Composition

Rank Sector Weight
1 Technology 6.44%
2 Industrials 4.65%
3 Healthcare 4.47%
4 Consumer Discretionary 4.32%
5 Financials 3.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PBR.A icon
3476
Petrobras Class A
PBR.A
$104B
$58K ﹤0.01%
8,230
-55,588
-87% -$461K
SVRA icon
3477
Savara
SVRA
$1.08B
$58K ﹤0.01%
53,543
+45,375
+556% +$77.6K
TRAK icon
3478
ReposiTrak
TRAK
$152M
$58K ﹤0.01%
11,843
-9,856
-45% -$45.9K
PHAS
3479
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$58K ﹤0.01%
16,665
+13,605
+445% +$54.8K
TRIL
3480
DELISTED
Trillium Therapeutics Inc.
TRIL
$58K ﹤0.01%
4,100
+2,387
+139% +$23.8K
DCOM
3481
DELISTED
Dime Community Bancshares
DCOM
$58K ﹤0.01%
5,146
-4,642
-47% -$57.7K
EAF icon
3482
GrafTech
EAF
$201M
$57K ﹤0.01%
837
+810
+3,000% +$56.5K
IGM icon
3483
iShares Expanded Tech Sector ETF
IGM
$10.9B
$57K ﹤0.01%
+1,104
New +$55.7K
LNAI
3484
Lunai Bioworks
LNAI
$10.2M
$57K ﹤0.01%
200
+157
+365% +$49.5K
SLDB icon
3485
Solid Biosciences
SLDB
$974M
$57K ﹤0.01%
1,855
+1,518
+450% +$58.1K
GTHX
3486
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$57K ﹤0.01%
4,887
+33
+0.7% +$545
REV
3487
DELISTED
Revlon, Inc.
REV
$57K ﹤0.01%
9,073
+6,706
+283% +$51.3K
BRFS
3488
DELISTED
BRF SA
BRFS
$56K ﹤0.01%
+16,976
New +$65.1K
CYBR
3489
DELISTED
CyberArk
CYBR
$56K ﹤0.01%
543
-1,349
-71% -$145K
MGNX icon
3490
MacroGenics
MGNX
$259M
$56K ﹤0.01%
2,224
-4,215
-65% -$115K
TEF
3491
DELISTED
Telefonica
TEF
$56K ﹤0.01%
19,315
+8,394
+77% +$29.5K
SBT
3492
DELISTED
Sterling Bancorp, Inc. Common Stock
SBT
$56K ﹤0.01%
18,545
+15,030
+428% +$48K
SMAR
3493
DELISTED
Smartsheet Inc.
SMAR
$56K ﹤0.01%
1,124
-3,103
-73% -$150K
FVAC.U
3494
DELISTED
Fortress Value Acquisition Corp. Units, each consisting of one share of Class A common stock and one
FVAC.U
$56K ﹤0.01%
3,755
+398
+12% +$5.39K
AVDL
3495
DELISTED
Avadel Pharmaceuticals
AVDL
$55K ﹤0.01%
+10,937
New +$79.6K
EVR icon
3496
Evercore
EVR
$12B
$55K ﹤0.01%
842
-2,558
-75% -$155K
BINI
3497
DELISTED
Bollinger Innovations
BINI
– –
0
– –
PCRX icon
3498
Pacira BioSciences
PCRX
$924M
$55K ﹤0.01%
918
-2,954
-76% -$172K
SA
3499
Seabridge Gold
SA
$3.5B
$55K ﹤0.01%
2,956
+2,935
+13,976% +$55K
UI icon
3500
Ubiquiti
UI
$35B
$55K ﹤0.01%
331
-602
-65% -$106K
138 139
140
141 142

Similar funds

CA
CSM Advisors Warrendale, Pennsylvania $4.07B AUM 29.62% 1-Year Est. Return
AP
Altarock Partners West Palm Beach, Florida $4.13B AUM 0.04% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.04B AUM 1.15% 1-Year Est. Return
JSW
Journey Strategic Wealth Summit, New Jersey $4.03B AUM 33.12% 1-Year Est. Return
GCM
Graham Capital Management Rowayton, Connecticut $4.14B AUM 17.82% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Tower Research Capital (TRC)'s Q3 2020 Portfolio in Review

As of Q3 2020, Tower Research Capital (TRC) held 5,395 positions worth $9.03B, up 271% from $2.44B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Tower Research Capital (TRC) deployed $1.53B of net new capital in Q3 2020, opening 546 new positions and adding to 3,017 existing holdings. Its largest new stake was iShares Biotechnology ETF: 34,723 shares worth $4.7M.

By sector, the portfolio is most concentrated in Technology at 6.4% of assets, down from 12% a quarter earlier, followed by Industrials and Healthcare.

On the sell side, the largest reduction was Vanguard S&P 500 ETF, an estimated $38.5M trimmed.

  • Tower Research Capital (TRC)'s largest Q3 2020 buy was iShares Biotechnology ETF: 34,723 shares worth $4.7M.
  • Tower Research Capital (TRC) added most to State Street SPDR S&P 500 ETF Trust in Q3 2020, an estimated $487M increase.
  • Tower Research Capital (TRC)'s biggest Q3 2020 reduction was Vanguard S&P 500 ETF, cutting an estimated $38.5M.
  • Tower Research Capital (TRC) fully exited iPath Series B S&P 500 VIX Short-Term Futures ETN in Q3 2020, selling an estimated $51.8M.
  • Tower Research Capital (TRC)'s ten largest holdings make up 64% of its $9.03B portfolio in Q3 2020.
  • Tower Research Capital (TRC) opened 546 new positions and closed 466 in Q3 2020.
  • Tower Research Capital (TRC)'s portfolio value rose 271% quarter-over-quarter to $9.03B.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2020, filed 16 Nov 2020.